FDA — authorised 27 February 1957
- Status: approved
🇺🇸 Trilafon in United States
FDA authorised Trilafon on 27 February 1957
Marketing authorisations
FDA — authorised 27 February 1957
- Application: NDA010775
- Marketing authorisation holder: SCHERING
- Local brand name: TRILAFON
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 29 January 1958
- Application: NDA011213
- Marketing authorisation holder: SCHERING
- Local brand name: TRILAFON
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 12 December 1958
- Application: NDA011557
- Marketing authorisation holder: SCHERING
- Local brand name: TRILAFON
- Indication: CONCENTRATE — ORAL
- Status: approved
FDA — authorised 10 September 1987
- Application: ANDA089457
- Marketing authorisation holder: ANI PHARMS
- Local brand name: PERPHENAZINE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 10 September 1987
- Application: ANDA089707
- Marketing authorisation holder: ANI PHARMS
- Local brand name: PERPHENAZINE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 10 September 1987
- Application: ANDA089708
- Marketing authorisation holder: ANI PHARMS
- Local brand name: PERPHENAZINE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 10 September 1987
- Application: ANDA089456
- Marketing authorisation holder: ANI PHARMS
- Local brand name: PERPHENAZINE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 8 December 1988
- Application: ANDA089684
- Marketing authorisation holder: SANDOZ
- Local brand name: PERPHENAZINE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 8 December 1988
- Application: ANDA089685
- Marketing authorisation holder: SANDOZ
- Local brand name: PERPHENAZINE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 8 December 1988
- Application: ANDA089686
- Marketing authorisation holder: SANDOZ
- Local brand name: PERPHENAZINE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 8 December 1988
- Application: ANDA089683
- Marketing authorisation holder: SANDOZ
- Local brand name: PERPHENAZINE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 31 December 1998
- Application: ANDA040226
- Marketing authorisation holder: PH HEALTH
- Local brand name: PERPHENAZINE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 25 May 2001
- Application: ANDA040360
- Marketing authorisation holder: PHARM ASSOC
- Local brand name: PERPHENAZINE
- Indication: CONCENTRATE — ORAL
- Status: approved
FDA — authorised 17 December 2015
- Application: ANDA205973
- Marketing authorisation holder: WILSHIRE PHARMS INC
- Local brand name: PERPHENAZINE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 17 October 2016
- Application: ANDA207582
- Marketing authorisation holder: WATSON LABS INC
- Local brand name: PERPHENAZINE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 14 April 2017
- Application: ANDA206691
- Marketing authorisation holder: MYLAN
- Local brand name: PERPHENAZINE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 1 March 2019
- Application: ANDA205056
- Marketing authorisation holder: RISING
- Local brand name: PERPHENAZINE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 6 April 2020
- Application: ANDA205232
- Marketing authorisation holder: ZYDUS PHARMS
- Local brand name: PERPHENAZINE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 18 May 2022
- Application: ANDA210163
- Marketing authorisation holder: APPCO
- Local brand name: PERPHENAZINE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 6 May 2024
- Application: ANDA212545
- Marketing authorisation holder: MACLEODS PHARMS LTD
- Local brand name: PERPHENAZINE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 18 March 2025
- Application: ANDA213694
- Marketing authorisation holder: JUBILANT GENERICS
- Local brand name: PERPHENAZINE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: NDA011294
- Marketing authorisation holder: SCHERING
- Local brand name: TRILAFON
- Indication: SYRUP — ORAL
- Status: approved
FDA
- Application: NDA011361
- Marketing authorisation holder: SCHERING
- Local brand name: TRILAFON
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
Trilafon in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Neuroscience approved in United States
Frequently asked questions
Is Trilafon approved in United States?
Yes. FDA authorised it on 27 February 1957; FDA authorised it on 27 February 1957; FDA authorised it on 29 January 1958.
Who is the marketing authorisation holder for Trilafon in United States?
Marketing authorisation holder not available in our data.